FGF19 and cholestasis: Because hydrophobic bile acid-induced damage to hepatocytes and bile duct epithelial cholangiocytes is a key pathogenic driver in cholestasis, FGF19 analogue that inhibits bile acid synthesis and apical sodium-dependent bile acid transporter (ASBT) inhibitor that blocks intestine bile acid reuptake have been tested as potential treatments for various forms of human cholestasis (7, 8, 9, 10, 11).